Celgene Investor Fact Sheet

CELGENE PROFILE

Celgene Corporation, as a leader in global biotechnology, has built an integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.

BUILDING ON SUCCESS

Celgene Corporation is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving commercial success and profitability are marketed products, which include THALOMID® (thalidomide), ALKERAN® (melphalan), Focalin®, cellular and tissue therapeutics, as well as the Ritalin® family of drugs.

REVENUES, R&D, & EPS



NEWS EVENTS

- Celgene announced adjusted diluted earnings per share of $0.10 for the quarter ended December 31, 2004, driven by record product sales. Total revenue for the fourth quarter increased 31% to $105.4 million from $80.8 million for the prior-year quarter. THALOMID net sales in the fourth quarter of 2004 increased 31% to $86.1 million from $65.6 million in the fourth quarter of 2003. Celgene posted fourth quarter adjusted net income of $17.3 million, or adjusted earnings of $0.10 per diluted share compared to net income of $5.4 million or $0.03 per share in the fourth quarter of last year. Sequentially, total revenue increased approximately 4% to $105.4 million in the fourth quarter from $101.5 million in the third quarter of 2004, with THALOMID sales rising about 9.4% quarter-over-quarter to $86.1 million from $78.7 million.
- In March both REVLIMID Pivotal Phase III Multiple Myeloma Trials in patients with relapsed or refractory multiple myeloma. exceeded pre-specified endpoints for interim efficacy and based on that, Celgene planned to unblind the studies and allow all patients in these studies access to REVLIMID. Celgene has initiated discussions with the FDA and international regulatory authorities regarding the submission of this data for potential approval. Plans being formulated to create expanded access programs for patients with previously treated myeloma
- In February clinical data from a Celgene sponsored Phase I/II trial evaluating REVLIMID in myelodysplastic syndromes was reported in The New England Journal of Medicine. 63% of transfusion dependent patients, on an intent-to-treat-basis, achieved transfusion independence and ten of 12 patients with the 5q deletion chromosomal abnormality achieved transfusion independence accompanied by complete cytogenetic response (disappearance) of chromosomal abnormalities.
- Celgene licensed patents to Roche, Barr Pharmaceuticals, Inc., and Mylan/Bertek on behalf of Genpharm, Ranbaxy directed to safely delivering isotretinoin in potentially high-risk patient populations. The patents are directed to, among other things, Celgene's proprietary S.T.E.P.S. (System for Thalidomide Education and Prescribing Safety) program.
- Celgene filed an investigational new drug (IND) application for its initial stem cell trial in a sickle cell anemia program that was accepted by the FDA. This Phase I trial will study stem cells from Celgene Cellular Therapeutics' cord blood bank and evaluate a small group of patients along a variety of clinical parameters.
- A Phase II trial of REVLIMID plus dexamethasone demonstrated twenty-five of 30 patients achieved an objective response yielding a response rate of 83% at the time of the presentation at the American Association of Hematology (ASH) 46th Annual Meeting in December.
- Also at ASH, a Phase II study of REVLIMID as a new therapeutic approach for patients with relapsed/refractory multiple myeloma using the combination doxil, vincristine, reduced frequency dexamethasone and REVLIMID (DVd-R) showed clinical benefit based on a response rate of greater than 66%.
- And another study at ASH evaluating the treatment of newly diagnosed multiple myeloma patients with an oral combination therapy of melphalan, prednisone and thalidomide (MPT) showed a statistically significant difference in event-free survival of 25.2 months versus 13.7 months compared to melphalan and prednisone (MP) alone.
- Celgene and Pharmion announced an expansion of their thalidomide development and commercialization collaboration following Celgene's October acquisition of Penn T, a worldwide supplier of thalidomide for both Celgene and Pharmion.

CELGENE CORPORATION

86 Morris Avenue
Summit, NJ 07901
P: 908-673-9000
F: 908-673-9001
www.celgene.com

PRODUCT PIPELINE



INVESTOR CONTACT INFORMATION

Robert J. Hugin, SVP and CFO
Email: rhugin@celgene.com

Brian Gill, Director of IR/PR
Email: bgill@celgene.com

CELGENE EXECUTIVE OFFICERS

John W. Jackson
Chairman and Chief Executive Officer

Sol J. Barer, Ph.D.
President and Chief Operating Officer

Robert J. Hugin
Senior Vice President
and Chief Financial Officer

ANALYST COVERAGE

Bear Stearns & Company
CE Unterberg & Co.
Citigroup Smith Barney
Friedman, Billings, Ramsey
JMP Securities LLC
JP Morgan Chase & Company
Leerink Swann & Company
Lehman Brothers
Merrill Lynch & Co.
Morgan Stanley
Natexis Bleichroeder
Prudential Securities
Thomas Weisel Partners
R.W. Baird

INVESTMENT CONSIDERATIONS

- Profitable and accelerating revenue growth supporting development of multiple clinical compounds across several high potential programs
- Lead clinical candidate REVLIMID offers near-term transforming potential as new innovative approach in treating cancer and inflammatory diseases
- Cutting edge research in cellular signaling technology delivering next generation therapies with potential to change standard of care
- Strong, evolving intellectual property estate supporting a broad, deep, unencumbered proprietary pipeline, in strategic programs, addressing large commercial opportunities
- Strong financial resources with close to $800 million in cash & investments positioned to support long-term growth strategy
- Effective senior management team experienced in successful execution of corporate strategies

Spring 2005 Investor Fact Sheet